THX-B|cas:1372206-64-8|西域试剂

THX-B,98.87%

产品编号：Bellancom-137322| CAS NO：1372206-64-8| 分子式：C₁₆H₂₄N₆O₄| 分子量：364.40

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-137322	￥600.00	杭州北京（现货）
Bellancom-137322	￥1000.00	杭州北京（现货）
Bellancom-137322	￥2000.00	杭州北京（现货）
Bellancom-137322	￥3200.00	杭州北京（现货）
Bellancom-137322	￥5000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

THX-B

产品介绍

THX-B 是一种有效的、非多肽类型的 p75^NTR (神经营养蛋白受体 p75) 拮抗剂。THX-B 可用于糖尿病、肾病、神经退行性和炎症性疾病的研究。

生物活性

THX-B is a potent and non-peptidic p75^NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders.

体外研究

THX-B (10 μM, 4 days) decreases proliferation of myoblasts.
THX-B (10 μM, 1 h) inhibits NGF-induced phosphorylation of ERK1/2 in C2C12 myoblasts.
THX-B (20 μM, 24 h) decreases photoreceptor cell death and reactive gliosis in cultured rd10 retinas.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	C2C12 myoblasts
Concentration:	10 μM
Incubation Time:	Pre-treated for 1 hour
Result:	Inhibited βNGF-induced ERK2 phosphorylation by 67%. Inhibited proNGF-induced ERK2 phosphorylation by 90%.

Immunofluorescence

Cell Line:	Cultured P22 rd10 retinas.
Concentration:	20 μM
Incubation Time:	24 h
Result:	Attenuated the thickening and enlargement of processes of astrocytes and Müller glia cells.

体内研究
(In Vivo)

THX-B (50 μg in 125 μL PBS, i.p. weekly for 4 weeks) improves bladder function in a mouse model of diabetic voiding dysfunction.
THX-B (2 μL of 2 μg/μL, IVT injection, a single dose) elicits a neuroprotective effect on photoreceptor cells in P17 rd10 mice.
THX-B (40 μg in 20 μL, IVT injection) resolves the inflammatory, vascular, and neurodegenerative phases of the retinal pathology^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse model of diabetic voiding dysfunction
Dosage:	50 μg in 125 μL PBS
Administration:	Intraperitoneal injection (i.p.)
Result:	Prevented bladder weight increase, which was 18% (95% CI 3%, 32%) and 37% (95% CI 14%, 60%) lower after 2 and 4 weeks of treatment.

Animal Model:	P17 rd10 mice
Dosage:	2 μL of 2 μg/μL, single dose
Administration:	Intravitreal (IVT) injected in one eye
Result:	Increased the number of photoreceptor rows as well as the ONL/INL ratio. Decreased the total number of microglial cells in the treated retinas, as well as some of the inflammatory signs, such as GFAP, α2M and the proinflammatory cytokines IL-1β and TNFα.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse model of diabetic voiding dysfunction
Dosage:	50 μg in 125 μL PBS
Administration:	Intraperitoneal injection (i.p.)
Result:	Prevented bladder weight increase, which was 18% (95% CI 3%, 32%) and 37% (95% CI 14%, 60%) lower after 2 and 4 weeks of treatment.

Animal Model:	P17 rd10 mice
Dosage:	2 μL of 2 μg/μL, single dose
Administration:	Intravitreal (IVT) injected in one eye
Result:	Increased the number of photoreceptor rows as well as the ONL/INL ratio. Decreased the total number of microglial cells in the treated retinas, as well as some of the inflammatory signs, such as GFAP, α2M and the proinflammatory cytokines IL-1β and TNFα.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse model of diabetic voiding dysfunction
Dosage:	50 μg in 125 μL PBS
Administration:	Intraperitoneal injection (i.p.)
Result:	Prevented bladder weight increase, which was 18% (95% CI 3%, 32%) and 37% (95% CI 14%, 60%) lower after 2 and 4 weeks of treatment.

Animal Model:	P17 rd10 mice
Dosage:	2 μL of 2 μg/μL, single dose
Administration:	Intravitreal (IVT) injected in one eye
Result:	Increased the number of photoreceptor rows as well as the ONL/INL ratio. Decreased the total number of microglial cells in the treated retinas, as well as some of the inflammatory signs, such as GFAP, α2M and the proinflammatory cytokines IL-1β and TNFα.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (274.42 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7442 mL	13.7212 mL	27.4424 mL
5 mM	0.5488 mL	2.7442 mL	5.4885 mL
10 mM	0.2744 mL	1.3721 mL	2.7442 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献